Maxime Verhoeven

118 Chapter 6 SUPPLEMENTARY FILE Supplementary Figure S1 shows the patients disposition during the U-Act-Early trial. Eighty (80) patients dropped out due to various reasons (e.g., AE, insufficient response, withdrawal of consent or other). Supplementary Figure S1 Flowchart, patient disposition during U-Act-Early trial. TCZ+MTX= tocilizumab + methotrexate initiation strategy group; TCZ= tocilizumab + placebo-methotrexate initiation strategy group; MTX= methotrexate + placebo-tocilizumab initiation strategy group; Withdr. consent= withdraw of consent; AE= adverse event; Insuff. Resp.= insufficient response. Supplementary Table S1 provides information about patients who were included and those not included in the post-trial follow-up. No significant differences were shown at start of U-Act-Early between those 2 groups. However, a worse effectiveness and safety profile and shorter follow-up time (drop-out because of ineffectiveness or SAE) were present in patients not included in the post-trial follow-up compared with patients included in the post-trial follow-up at last visit of the U-Act-Early trial, Supplementary Table S1.